Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SUM1315MO2 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 0.000236 | uM | 7529.078 | 0.9359 | 0.8334 | 0.7619 | |
| SUM1315MO2 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 0.00118 | uM | 7529.078 | 0.9754 | 0.9358 | 0.7619 | |
| SUM1315MO2 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 0.00589 | uM | 7529.078 | 0.9568 | 0.8873 | 0.7619 | |
| SUM1315MO2 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 0.0294 | uM | 7529.078 | 0.9168 | 0.7844 | 0.7619 | |
| SUM1315MO2 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 0.147 | uM | 7529.078 | 0.6907 | 0.2305 | 0.7619 | |
| SUM1315MO2 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 0.736 | uM | 7529.078 | 0.5146 | -0.1638 | 0.7619 | |
| SUM1315MO2 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 3.68 | uM | 7529.078 | 0.0329 | -0.9774 | 0.7619 | |
| SUM1315MO2 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 18.4 | uM | 7529.078 | 0.0334 | -0.9769 | 0.7619 | |
| SUM1315MO2 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 92 | uM | 7529.078 | 0.0286 | -0.9811 | 0.7619 | |
| SUM1315MO2 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 0.000221 | uM | 10139.034 | 1.0375 | 1.0897 | 0.8381 | |
| SUM1315MO2 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 0.0011 | uM | 10139.034 | 1.0092 | 1.0219 | 0.8381 | |
| SUM1315MO2 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 0.00552 | uM | 10139.034 | 1.0038 | 1.0090 | 0.8381 | |
| SUM1315MO2 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 0.0276 | uM | 10139.034 | 0.9126 | 0.7933 | 0.8381 | |
| SUM1315MO2 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 0.138 | uM | 10139.034 | 0.8851 | 0.7290 | 0.8381 | |
| SUM1315MO2 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 0.69 | uM | 10139.034 | 0.6423 | 0.1794 | 0.8381 | |
| SUM1315MO2 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 3.45 | uM | 10139.034 | 0.2240 | -0.6644 | 0.8381 | |
| SUM1315MO2 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 17.2 | uM | 10139.034 | 0.1244 | -0.8337 | 0.8381 | |
| SUM1315MO2 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 86.2 | uM | 10139.034 | 0.0883 | -0.8895 | 0.8381 | |
| SUM159PT | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 0.000221 | uM | 7918.007 | 0.7387 | 0.8065 | 2.9756 | |
| SUM159PT | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 0.0011 | uM | 7918.007 | 0.9399 | 0.9588 | 2.9756 | |
| SUM159PT | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 0.00552 | uM | 7918.007 | 0.9506 | 0.9662 | 2.9756 | |
| SUM159PT | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 0.0276 | uM | 7918.007 | 0.8529 | 0.8959 | 2.9756 | |
| SUM159PT | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 0.138 | uM | 7918.007 | 0.3407 | 0.3928 | 2.9756 | |
| SUM159PT | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 0.69 | uM | 7918.007 | 0.0856 | -0.1244 | 2.9756 | |
| SUM159PT | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 3.45 | uM | 7918.007 | 0.0592 | -0.2266 | 2.9756 |